Somaxon Pharmaceuticals to Present at the JPMorgan Healthcare Conference
SAN DIEGO, CA – January 3, 2007 – Somaxon Pharmaceuticals, Inc. (NASDAQ: SOMX) today announced that Ken Cohen, president and chief executive officer, will present a company update at the JPMorgan Healthcare Conference at The Westin St. Francis, San Francisco, on Wednesday, January 10, 2007, at 10:30 a.m. Pacific Time (1:30 p.m. Eastern Time).
A live webcast of the presentation will be available in the Investor Relations section of the company’s website under Event Scheduler at www.somaxon.com. The webcast will be archived and accessible for at least 14 days.
About Somaxon Pharmaceuticals
Headquartered in San Diego, CA, Somaxon Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the in-licensing and development of proprietary product candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology. Somaxon has completed four successful Phase 3 clinical trials for its lead product candidate, SILENOR™ (doxepin HCl) for the treatment of insomnia. Somaxon expects to file a New Drug Application with the U.S. Food and Drug Administration for SILENOR™ in the third quarter of 2007, assuming that its preclinical studies are successful and proceed as currently scheduled. Somaxon has completed a pilot Phase 2 trial for nalmefene in smoking cessation with positive results and a Phase 2/3 clinical trial for nalmefene for the treatment of pathological gambling that did not achieve statistical significance for the primary or secondary endpoints. The company will evaluate the results from both of these trials before making determinations regarding the future of the nalmefene program. Acamprosate Ca, a potential treatment for movement disorders, is currently in formulation development.
For more information, please visit the company’s web site at www.somaxon.com.
- Contact Information
- Meg McGilley
- Chief Financial Officer
- Somaxon Pharmaceuticals
- Contact via E-mail
This news content was configured by WebWire editorial staff. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.